VECTrans®

VECT-HORUS has set up a unique screening platform of peptide and VHH (single-domain antibody; sdAb) libraries to identify and optimize RMT-based vectors that bind receptors expressed at the BBB such as the Low-Density Lipoprotein Receptor (LDLR). The company has also an ongoing R&D program on other RMT systems for brain or peripheral delivery.

VECT-HORUS has demonstrated its capability to :

  • Conjugate its vectors to different types of molecules and macromolecular complexes of interest:
    • Small organic molecules such as fluorophores, anticancer drugs, chelating agents such as DOTA or NODAGA…
    • Peptides: neuropeptides, analgesic peptides…
    • Proteins: therapeutic proteins, enzyme replacement therapy for rare and orphan diseases, monoclonal antibodies…
    • Oligonucleotides: antisense oligos, siRNAs……
    • Lipid-nanoparticles
  • Transport conjugates: first in vitro into different cell types expressing the target receptors, including endothelial cells of the BBB, and in vivo across the BBB, or in glioblastoma and other cancers such as pancreatic and adrenal tumours.
  • Evaluate the Proof-Of-Concept of various conjugates in various animal models (hypothermia, analgesia, neuroprotection…). One of these conjugates, VH-N439 is currently in regulatory preclinical phase. VH-N439 is a new chemical entity based on the conjugation of one of the Company’s peptide-vectors to an analogue of neurotensin, a neuropeptide that induces hypothermia when administered directly in the brain but that does not cross the BBB when administered systemically in its native form.

VECT-HORUS technology advantages :

  • Short (8-10 amino-acids), cyclic, chemically optimized peptides.
  • Stable peptide vectors (half-life in fresh blood from 1h30 to more than 9h, depending on the vectors)
  • Do not compete with the natural ligand of the receptor
  • Alternative VHH-based vectors.
  • Development of vectors that present the potential to bind cross species (rodents, human) for optimal development, pre-clinical and clinical.
  • Customized conjugates depending on the cargo and the organ to target.

Intellectual property & publications

5 FAMILIES OF PATENTS

3 international patent applications for vectors

  • Peptide derivatives and use thereof as carriers for molecules in the form of conjugates (Application WO 2010/046588).
  • Peptide derivatives, preparation thereof and uses thereof (Application WO 2011/131896).
  • Compositions and methods for drug delivery (Application WO 2014/060601).

1 international patent application for a vectorised neuroprotective agent

  • Activated neurotensin molecules and the uses thereof (Application WO 2015/107182).

1 international patent application for uses of vectors in cancer imaging and radiotherapy

  • Compositions and methods for cancer imaging and radiotherapy (Application WO 2018/138372).

Reviews and scientific publications

Pipeline & alliances

By leveraging its proprietary technology platform VECT-HORUS has developed a hybrid business model.

Internal pipeline of proprietary drug candidates

VECT-HORUS is building a pipeline of proprietary drug candidates for internal development up to until preclinical or early clinical trials. These products are available for licensing-out.

External collaborations with partners

VECT-HORUS’ highly innovative technology platform is available to pharmaceutical and biotech partners to transport their drugs into the brain and other organs. The Company has combined solid competences and expertise in various R&D areas and has set up well-structured and state of the art technological platforms. The Company has various ongoing collaborations in different domains (CNS, NDD, cancer imaging and treatment, etc.).